European Lung Cancer Working Party
12
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.7%
2 terminated/withdrawn out of 12 trials
75.0%
-11.5% vs industry average
25%
3 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Bronchoscopy Assisted by Electromagnetic Navigation (EMN) in the Diagnosis of Small Pulmonary Nodules
Role: lead
Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Role: lead
Has Inflammation a Significant Implication in Lung Cancer Evolution?
Role: lead
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
Role: lead
Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry
Role: lead
Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer
Role: lead
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
Role: lead
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
Role: lead
Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
Role: lead
Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy
Role: lead
Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer
Role: lead
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
Role: lead
All 12 trials loaded